Skip to content

Remdesivir for the Treatment of Covid-19 — Final Report

John H. Beigel, Kay M Tomashek, Lori Elizabeth Dodd, Aneesh K. Mehta, Barry S. Zingman, André C. Kalil, Elizabeth L. Hohmann, Helen Y. Chu, Annie F. Luetkemeyer, Susan Kline, Diego López de Castilla, Robert W. Finberg, Kerry L. Dierberg, Victor F. Tapson, Lanny L. Hsieh, Thomas F. Patterson, Roger Paredes, Daniel A Sweeney, William R. Short, Giota Touloumi, David Chien Lye, Norio Ohmagari, Myoung‐don Oh, Guillermo Miguel Ruiz-Palacios, Thomas Benfield, Gerd Fätkenheuer, Mark G. Kortepeter, Robert L. Atmar, Clarence Buddy Creech, Jens Dilling Lundgren, Abdel G. Babiker, Sarah Lilian Pett, James D. Neaton, Timothy H. Burgess, Tyler Bonnett, Mat Makowski, Anu O Osinusi, Seema Nayak, Henry Clifford Lane

New England Journal of Medicine · 2020 · 7,417 citationsOpen access

No retraction on record in OpenAlex.Check Crossref now

Cite this paper

Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E. L., Chu, H. Y., Luetkemeyer, A. F., Kline, S., Castilla, D. L. de, Finberg, R. W., Dierberg, K. L., Tapson, V. F., Hsieh, L. L., Patterson, T. F., Paredes, R., Sweeney, D. A., Short, W. R., … Lane, H. C. (2020). Remdesivir for the treatment of Covid-19 — final report. New England Journal of Medicine, 383(19), 1813–1826. https://doi.org/10.1056/nejmoa2007764

In text: (Beigel et al., 2020)

Ask a question about this research

One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.

Abstract

BACKGROUND: Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be efficacious. METHODS: We conducted a double-blind, randomized, placebo-controlled trial of intravenous remdesivir in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection. Patients were randomly assigned to receive either remdesivir (200 mg loading dose on day 1, followed by 100 mg daily for up to 9 additional days) or placebo for up to 10 days. The primary outcome was the time to recovery, defined by either discharge from the hospital or hospitalization for infection-control purposes only. RESULTS: A total of 1062 patients underwent randomization (with 541 assigned to remdesivir and 521 to placebo). Those who received remdesivir had a median recovery time of 10 days (95% confidence interval [CI], 9 to 11), as compared with 15 days (95% CI, 13 to 18) among those who received placebo (rate ratio for recovery, 1.29; 95% CI, 1.12 to 1.49; P<0.001, by a log-rank test). In an analysis that used a proportional-odds model with an eight-category ordinal scale, the patients who received remdesivir were found to be more likely than those who received placebo to have clinical improvement at day 15 (odds ratio, 1.5; 95% CI, 1.2 to 1.9, after adjustment for actual disease severity). The Kaplan-Meier estimates of mortality were 6.7% with remdesivir and 11.9% with placebo by day 15 and 11.4% with remdesivir and 15.2% with placebo by day 29 (hazard ratio, 0.73; 95% CI, 0.52 to 1.03). Serious adverse events were reported in 131 of the 532 patients who received remdesivir (24.6%) and in 163 of the 516 patients who received placebo (31.6%). CONCLUSIONS: Our data show that remdesivir was superior to placebo in shortening the time to recovery in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection. (Funded by the National Institute of Allergy and Infectious Diseases and others; ACTT-1 ClinicalTrials.gov number, NCT04280705.).

  1. Clinical Characteristics of Coronavirus Disease 2019 in China2020
  2. A Novel Coronavirus from Patients with Pneumonia in China, 20192020
  3. A pneumonia outbreak associated with a new coronavirus of probable bat origin2020
  4. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China2020
  5. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine2020

Metadata from OpenAlex (CC0). Citations are generated from the published record.